Hoya (TSE:7741) Stock Valuation After FDA Clearance For New Endoscopy Devices
Simply Wall St
Last updated: June 15, 2026
HOYA has received US FDA clearance for new PENTAX Medical i20c Video Endoscope models, expanding its gastrointestinal endoscopy offerings. This news comes amidst mixed recent stock performance, with strong long-term gains but a recent dip.
- HOYA's stock has seen a 60.56% total shareholder return over the past year. Currently trading at ¥26,420, it is approximately 14% below the analyst price target of ¥30,113. The company's Price-to-Earnings (P/E) ratio is 35x, which is considered expensive compared to its own cash flow valuation, the peer average of 25.5x, and the Japan Medical Equipment industry average of 14.9x. A discounted cash flow (DCF) model suggests a future cash flow value of ¥22,878.87 per share, also indicating overvaluation.
- Key risks for HOYA include potential slowdowns in annual revenue or net income growth and weaker performance in major markets like the US and China. The article suggests exploring other investment opportunities in the medtech sector.
